FTO inhibitor-loaded glutathione-bioimprinted nanocomposites (GNPIPP12MA) are engineered to target the FTO/m6A pathway with glutathione depletion for synergistically improving anti-leukemia treatment efficiency. This evidence concerns the gene FTO and leukemia.